Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches

被引：7

作者：

D'Amico, Carmine ^{[1
]}

Fusciello, Manlio ^{[2
]}

Hamdan, Firas ^{[2
]}

D'Alessio, Federica ^{[2
]}

Bottega, Paolo ^{[2
]}

Saklauskaite, Milda ^{[2
]}

Russo, Salvatore ^{[2
]}

Cerioni, Justin ^{[2
]}

Elbadri, Khalil ^{[1
]}

Kemell, Marianna ^{[3
]}

Hirvonen, Jouni ^{[1
]}

Cerullo, Vincenzo ^{[2
,4
,5
,6
,7
,8
]}

Santos, Helder A. ^{[1
,9
]}

机构：

[1] Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Chem & Technol, FI-00014 Helsinki, Finland

[2] Univ Helsinki, Fac Pharm, Dept Pharmaceut Biosci, Drug Res Program,ImmunoViroTherapy Lab, Viikinkaari 5,E00790, Helsinki, Finland

[3] Univ Helsinki, Fac Sci, Dept Chem, FI-00014 Helsinki, Finland

[4] Univ Helsinki, Helsinki Inst Life Sci HiLIFE, Fabianinkatu 33, Helsinki 00710, Finland

[5] Univ Helsinki, Fac Med, Translat Immunol Program TRIMM, Haartmaninkatu 8, Helsinki 00290, Finland

[6] Univ Helsinki, Digital Precis Canc Med Flagship iCAN, Helsinki 00014, Finland

[7] Naples Univ Federico II, Dept Mol Med & Med Biotechnol, I-80131 Naples, Italy

[8] Naples Univ Federico II, CEINGE, I-80131 Naples, Italy

[9] Univ Groningen, Univ Med Ctr Groningen UMCG, Personalized Med Res Inst PRECIS, Dept Biomat & Biomed Technol, NL-9713 AV Groningen, Netherlands

来源：

BIOACTIVE MATERIALS | 2025年 / 45卷

基金：

欧洲研究理事会;

关键词：

Microneedles; Cancer therapy; Adenoviral vector; Vaccine; DENDRITIC CELLS; DRUG; CHALLENGES; PAIN;

D O I：

10.1016/j.bioactmat.2024.11.006

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. This study aims at identifying the potential of MNs for the delivery of Peptidecoated Conditionally Replicating Adenoviruses (PeptiCRAd), whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens. The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure, induction of immune response, and tumor eradication. The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation in vivo, leading to complete tumor rejection when mice were pre-vaccinated. A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body. Thus, the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer, more tolerable, and efficient approach to cancer immunotherapy, potentially translatable to other therapeutic applications.

引用

页码：115 / 127

页数：13

共 58 条

[1] A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial [J].